Slides on Key Decisions in HIV Care: Weight Gain With Initial Therapy

See whether weight gain should or should not be a factor in determining initial therapy.
Joseph J. Eron, Jr., MD
Format: Microsoft PowerPoint (.ppt)
File Size: 304 KB
Released: August 2, 2021

Acknowledgements

Educational grant provided by:
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Related Content

Slides from Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 26, 2022

Clinical Care Options (CCO) expert insight by Dr Gail Matthews on what to consider when switching suppressed patients with HIV/HBV from oral to long-acting ART regimen

person default Prof Gail Matthews, MD, PhD Released: January 25, 2022

Slides from Dr John Baxter and Clinical Care Options (CCO): Transmitted drug resistance does not necessarily preclude the use of many first line ART options.

John D. Baxter, MD Released: January 24, 2022

Dr Mark Sulkowski and Clinical Care Options (CCO): Treatment of both HIV and HCV should be prioritized for patients that are coinfected with careful consideration of drug-drug interactions.

Mark S. Sulkowski, MD Released: January 19, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings